How to Fix the Protocol Complexity Problem - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
How to Fix the Protocol Complexity Problem

Source: Applied Clinical Trials

Would you delay protocol approval by two months if it meant your enrollment and retention would improve and, in turn, positively affect your data quality?

With all the data and downstream impact of a overly complex or poorly designed protocols in hand, it appears that this phenomenon is taking hold, but hasn’t hit mainstream yet. At CBI’s Clinical Trial Budgeting and Project Management conference earlier this week, sponsors shared both their successes and challenges in reigning in protocol creep.

There is no doubt that everything about protocol design has come under the microscope in the past couple of years. And it came to a head when Tufts CSDD announced its analysis of the costs surrounding protocol amendments and non-core protocol procedures. The Tufts analysis was based on data from Medidata Solutions’ PICAS database of industry-wide negotiated site cost information. Survey analyst Ken Getz noted that the key takeaway is “that study performance and efficiency are highly associated with protocol feasibility. Any and all attempts to simplify protocol design and reduce complexity will reduce cost, shorten cycle time, and improve patient recruitment and retention effectiveness.”

What this analysis did not directly quantify was the downstream effects of protocol complexity on recruitment and retention. Medidata itself delved into its Insights database to answer that question in this article, however, it did say the metrics used were from different areas of its data warehouse. So it found that there is an increase in protocol complexity and is accompanied by a downward trend in the ratio of enrolled-to-screened patients. However, “there is not a one-to-one direct relationship or correlation between protocol complexity in a study and enrollment rates in that same study, at a macro level, this analysis highlights that increasing complexity of protocols correlates with either higher patient screening or lower patient enrollment, or both.”

It is more than anecdotally correct that putting a patient first in the protocol design, as is heard at patient engagement conferences or in regard to patient-centric trial design, will increase both recruitment and retention rates.

Merck recently revamped its processes around site start-up—from site contracts to site readiness to how it works with its outsourcers—and reported increases in efficiencies at the conference. These changes started incrementally in 2012 throughout further implementation in 2013, which shows positive outcomes. However, next year should provide more in-depth data. 

Merck’s new protocol development process involves an Investigator Scientific Network that includes investigators who are also clinicians. Their input is usually centered on the different points related to standard of care and potentially point out that a procedure would not be necessary in a real-world setting. In addition to this network, Merck has instituted a process of three internal pre-reviews before protocol approval to apply the scientific rigor to a cost process.

Sponsor speakers at the conference noted it really is important to ask the medical officer or scientific lead if that one extra blood draw is necessary during the protocol development stage, and push back if the view is that it is not. Even a lead investigator or outside KOL with experience in the therapeutic area can offer real-world input into a protocol that can also help cut costs.

In site feasibility, it is crucial to go over the protocol from a patient’s journey. In one study described by a speaker from AstraZeneca, it was determined that enrolling in a stroke study in a hospital that potential patients were being missed. In an analysis of the emergency room procedures, it turned out that all stroke patients received oxygen from a nurse prior to the physician. The respiratory nurse was then educated on the protocol and asked to contact the clinical study nurse for potential screening. After that, the patients were no longer missed.

Transparency Life Sciences, which uses an online crowdsourcing protocol builder, was brought up by the speakers as an interesting approach for designing and streamlining protocols. The company most recently partnered with Icahn School of Medicine at Mount Sinai to design and conduct a trial assessing metformin as a treatment for prostate cancer. That trial will use crowdsourcing to obtain input into the design of the protocol, which will assess the use of telemonitoring to replace most patient visits.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here